![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Springe zu: 2025
Anzahl der Publikationen: 1
2025
Holzgreve, Adrien 
ORCID: https://orcid.org/0000-0002-9566-8438; Unterrainer, Lena M.; Tiling, Maximilian; Mansour, Nabeel ORCID: https://orcid.org/0000-0002-3467-1916; Spitzweg, Christine ORCID: https://orcid.org/0000-0002-0413-9697; Brendel, Matthias ORCID: https://orcid.org/0000-0002-9247-2843; Ricke, Jens; Unterrainer, Marcus ORCID: https://orcid.org/0000-0002-8238-1198; Kunz, Wolfgang G. ORCID: https://orcid.org/0000-0002-5021-1952 und Mehrens, Dirk ORCID: https://orcid.org/0000-0001-5114-8935
(2025):
Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trials.
In: Journal of Nuclear Medicine, Bd. 66, Nr. 7, jnumed.124.269416
[PDF, 865kB]
ORCID: https://orcid.org/0000-0002-9566-8438; Unterrainer, Lena M.; Tiling, Maximilian; Mansour, Nabeel ORCID: https://orcid.org/0000-0002-3467-1916; Spitzweg, Christine ORCID: https://orcid.org/0000-0002-0413-9697; Brendel, Matthias ORCID: https://orcid.org/0000-0002-9247-2843; Ricke, Jens; Unterrainer, Marcus ORCID: https://orcid.org/0000-0002-8238-1198; Kunz, Wolfgang G. ORCID: https://orcid.org/0000-0002-5021-1952 und Mehrens, Dirk ORCID: https://orcid.org/0000-0001-5114-8935
(2025):
Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trials.
In: Journal of Nuclear Medicine, Bd. 66, Nr. 7, jnumed.124.269416
[PDF, 865kB]